A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
Phase 1
- Conditions
- Nasopharyngeal Neoplasms
- Interventions
- Other: CAR-T cells
- Registration Number
- NCT02980315
- Lead Sponsor
- The Second Hospital of Nanjing Medical University
- Brief Summary
The purpose of this study is to evaluate the safety of the designed LMP1-CAR -T cells and determine whether the CAR-T cells are effective in the treatment of EBV associated malignant tumors.
- Detailed Description
Half of the patients will treat with LMP1-CAR-T cells,while the other half will receive a placebo.During the time of the treatment ,we will supervise the side effect of treated group.At last we compare the survival rate and health condition of the two groups.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Clinical diagnosis of nasopharyngeal carcinoma
Exclusion Criteria
-
•pregnant woman
- severe autoimmune diseases
- serious infection
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description CAR-T cells CAR-T cells the group treat with CAR-T cells
- Primary Outcome Measures
Name Time Method all cause mortality one year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
SecondNanjingMU
🇨🇳Nanjing, Jiangsu, China